课题基金 / 基金详情

Career Development Program

Career Development Program
职业发展计划
批准号:
7742551
负责人:
Michael Benjamin Atkins
金额:
$6.83万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-01 至 2014-05-31

项目摘要

项目成果

Michael Benjamin Atkins的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Career development activities were a major focus of the initial funding period of the Kidney Cancer SPORE. Many investigators within the DF/HCC Kidney Cancer SPORE have had a longstanding interest and substantial track record in mentoring of junior faculty with an interest in cancer research. The funding of the Kidney Cancer SPORE in 2003 enabled us to establish a formal process for the identification, selection, funding and mentoring of young investigators seeking to pursue careers in basic and clinical aspects of kidney cancer research. In addition, as this field has traditionally received only modest interest from young investigators, it enabled us to focus on marketing to young investigators the potential benefits of pursuing a research career focused on kidney cancer. We feel that our efforts to date have been an unqualified success, with no fewer than 15 young investigators establishing independent academic careers focused at least partially on kidney cancer as a consequence of their interactions with the SPORE. Several of these individuals are leading Kidney Cancer Programs at major academic institutions creating opportunities to multiply the impact of the SPORE on the field (see below and in the Career Development Program Progress Report). We have also been successful at obtaining institutional and outside support for the Career Development Program, which has added to our ability to support young faculty pursuing careers in kidney cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号:
    10462570
  • 项目类别:
  • 资助金额:
    $52.27万
  • 财政年份:
    2018
  • 负责人:
    Michael Benjamin Atkins
  • 依托单位:
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
  • 批准号:
    10001451
  • 项目类别:
  • 资助金额:
    $53.33万
  • 财政年份:
    2018
  • 负责人:
    Michael Benjamin Atkins
  • 依托单位:
Developmental Research Program
DF/HCC Renal Cancer SPORE
海外基金